Redefining the value of medicines with patients at the centre
November 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, health economics and outcomes research, market access, pharma
Liz Lewis, Head of Global Oncology Patient Value, Policy and Access at Takeda Oncology, discusses the importance and challenges of …
FDA approves RedHill Biopharma’s Talicia to combat Helicobacter pylori infection
November 4, 2019Sales and Marketing FDA, RedHill Biopharma, pharma
RedHill Biopharma is celebrating after the FDA chose to award marketing authorisation to Talicia (omeprazole magnesium, amoxicillin and rifabutin) for …
International revenue for world’s best-selling drug Humira falls 33.5% in the face of biosimilar competition
November 4, 2019Sales and Marketing AbbVie, Humira, pharma
With the release of its Q3 financial results, AbbVie confirmed that international revenues for its blockbuster therapy Humira (adalimumab) – …
Donald Trump nominates Dr Stephen Hahn as next FDA Commissioner
November 4, 2019Medical Communications, Sales and Marketing Donald Trump, FDA, Ned Sharpless, President trump, Scott Gottlieb, Trump, US
The US FDA could be set to receive its next long-term Commissioner after the White House revealed President Donald Trump’s …
China green lights first novel Alzheimer’s therapy since 2003
November 4, 2019Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma
Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …
Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes
November 4, 2019Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo
Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …
Current drugs are “poisoning” elderly patients due to insufficient trial data, House of Lords committee hears
November 1, 2019Medical Communications, Research and Development elderly patients, pharma, trial diversity
Elderly patients are being put at risk by prescriptions for drugs which have not been properly tested in their age …
England’s antibiotic use is down, but antibiotic-resistant infections still spreading, report warns
November 1, 2019Medical Communications, Research and Development Antibiotics, England, Review on antimicrobial resistance
A new report has revealed that GPs in England are writing fewer prescriptions for antibiotics, but this has done little …
Amgen drops $2.7bn to acquire stake in Chinese biotech in bid to expand in the region
November 1, 2019Medical Communications, Research and Development, Sales and Marketing Amgen, BeiGene, Cancer, China, deal, oncology, pharma
Amgen has signed an agreement with Chinese biotech BeiGene to acquire a 20.5% stake in the latter, in a bid …
Despite some advantages, Novartis’ Cosentyx fails to outclass Humira in active psoriatic arthritis
November 1, 2019Medical Communications, Research and Development Cosentyx, Humira, Novartis, active psoriatic arthritis, pharma
Novartis has announced new data drawn from a trial pitting Cosentyx (secukinumab) in head-to-head competition with AbbVie’s Humira (adalimumab) – …
Transactions in the pharma sector: Through the EU merger review looking-glass
October 31, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing mergers, mergers and acquisitions, pharma
With mergers and acquisitions back in full swing after a period of drought, Alec Burnside (Partner) and Delphine Strohl (Associate) …
AbbVie’s Rinvoq impresses at Phase 3 in active psoriatic arthritis sub-population
October 31, 2019Research and Development AbbVie, Rinvoq, pharma
AbbVie has unveiled new Phase 3 data on two doses of its JAK inhibitor Rinvoq (upadacitinib), showing that the therapy …
Catalyst’s lead candidate Firdapse falls short in Congenital Myasthenic Syndromes
October 31, 2019Research and Development Catalyst Pharmaceuticals, FDA, firdapse, pharma, trial failure
Catalyst Pharmaceuticals has made it known that its lead product Firdapse (Amifampridine Phosphate) fell short of its primary endpoint in …
Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate
October 31, 2019Research and Development Galapagos, Novartis, atopic dermatitis, morphosys, pharma
The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for …
Genmab’s Executive VP and CFO to retire in 2020
October 31, 2019Research and Development Genmab, appointment, pharma
David Eatwell, Executive Vice President and Chief Financial Officer at Genmab, has announced his intention to step down from the …
FDA committee votes to pull US approval for AMAG’s preterm birth drug Makena
October 31, 2019Sales and Marketing FDA, Makena, pharma
An FDA committee has passed a contentious vote recommending by a slim majority for the withdrawal of existing approval of …
The November 2019 issue of Pharmafocus is available to read for free online now!
October 30, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
The latest monthly edition of Pharmafocus, the November issue, is available to read for free online now!
FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis
October 30, 2019Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma
The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
FDA slams brakes on trial for world’s most expensive drug following safety concerns in children
October 30, 2019Research and Development FDA, Novartis, Zolgensma, pharma
The FDA has temporarily shut down a clinical trial evaluating Zolgensma – the world’s most expensive drug at $3.1 million …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
